According to statistics, in 2019, the AI ​​new drug research and development track disclosed a total of 6 financings, and the development was stable. For this track, high-value financing does not bring enough confidence to the industry. What companies and investors want to see more is the verification of the platform’s AI capabilities. The verification method can be that the R & D pipeline is paid by the pharmaceutical company, or it can be a positive clinical result.